Review of immediate-release omeprazole for the treatment of gastric acid-related disorders

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 14, 2005, Pages 2501-2510

  Castell, Donald ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Gastroesophageal reflux disease; Immediate release omeprazole; Proton pump inhibitor

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DIAZEPAM; DISULFIRAM; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROPRANOLOL; PROTON PUMP INHIBITOR; RABEPRAZOLE; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BLEEDING DISORDER; CLINICAL TRIAL; CONSTIPATION; CRITICAL ILLNESS; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG RELEASE; DRUG STRUCTURE; DUODENUM ULCER; ENTERIC COATED TABLET; GASTROINTESTINAL DISEASE; GASTROINTESTINAL REFLUX; HEADACHE; HUMAN; NAUSEA; POWDER; REFLUX ESOPHAGITIS; REVIEW; RISK REDUCTION; STOMACH ACID; STOMACH PH; STOMACH ULCER; STRUCTURE ANALYSIS; SUSPENSION; TREATMENT INDICATION; UPPER GASTROINTESTINAL BLEEDING;

ADMINISTRATION, ORAL; ANTI-ULCER AGENTS; CIRCADIAN RHYTHM; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; OMEPRAZOLE; PARIETAL CELLS, GASTRIC; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIALS;

EID: 28244492954     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.14.2501     Document Type: Review

References (38)

1. PILBRANT A, CEDERBERG C: Development of an oral formulation of omeprazole. Scand. J. Gastroenterol. (1985) 20(Suppl. 108):113-120.
2. BURNETT J, BALKIN ER: Evaluation of stability and viscosity of omeprazole immediate-release oral suspension at a concentration suitable for pediatric use. Gastroenterol. (2005) 128(4):A-524.
3. SHARMA VK, PEYTON B, SPEARS T: Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol. Ther. (2000) 14:887-892.
4. SONG JC, QUERCIA RA, FAN C: Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension. Am. J. Health Syst. Pharm. (2001) 58:689-694.
5. DUNN A, WHITE CM, REDDY P et al.: Delivery of omeprazole and lansoprazole granules through a nasogastric tube in vitro. Am. J. Health Syst. Pharm. (1999) 56:2327-2330.
6. SANTARUS INC: Zegerid® prescribing information. Santarus, Inc, San Diego (CA), USA (2004).
7. MODLIN IM, SACHS G (Eds): Acid Related Diseases-Biology and Treatment, 2nd edn. Lippincott Williams and Wilkins, Philadelphia (PA) USA (2004).
8. HATLEBAKK JG, KATZ PO, CAMACHO-LOBATO L, CASTELL DO: Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. (2000) 14:1267-1272.
9. ASTRAZENECA: Prilosec® prescribing information. AstraZeneca, Wilmington (DE), USA (2003).
10. TAP PHARMACEUTICALS INC: Prevacid® prescribing information. TAP Pharmaceuticals, Inc., Lake Forest (IL), USA (2004).
11. ASTRAZENECA: Nexium® prescribing information. AstraZeneca, Wilmington (DE), USA (2004).
12. WYETH PHARMACEUTICALS: Protonix® prescribing information. Wyeth Pharmaceuticals, Philadelphia (PA), USA (2004).
13. EISAI INC: Aciphex® prescribing information. Eisai, Inc., Teaneck (NJ), USA (2003).
14. HEPBURN B, HARDIMAN Y, FRANK W, GOLDLUST B: A loading dose regimen of omeprazole immediate-release oral suspension increases bioavailability (healthy subjects) and achieves rapid control of gastric acidity in critically ill patients. Digestive Disease Week (2004) Poster 100401.
15. LANGTRY HD, MARKHAM A: Rabeprazole, a review of its use in acid-related gastrointestinal disorders. Drugs (1999) 58:725-742.
16. LANGTRY HD, WILDE MI: Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs (1997) 54:473-500.
17. MEYER UA: Interaction of proton pump inhibitors with cytochrome P450: consequences for drug interactions. Yale J. Biol. Med. (1996) 69:203-209.
18. ANDERSSON T, MINERS JO, VERONESE ME: Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. (1993) 36:521-30.
19. CURI-PEDROSA R, PICHARD L, BONFILS C: Major implication of cytochrome P4503A4 in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes. Br. J. Clin. Pharmacol. (1993) 36:156P.
20. HUNT RH: Importance of PH control in the management of GERD. Arch. Intern. Med. (1999) 159:649-657.
21. SMYTHE MA, ZAROWITZ BJ: Changing perspectives of stress gastritis prophylaxis. Ann. Pharmacol. (1994) 28:1073-1085.
22. CONRAD S, GABRIELLI A, MARGOLIS B et al.: A randomized double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit. Care Med. (2005) 33:760-765.
23. GILLEN G, MCOLL KE: Problems related to acid rebound and tachyphylaxis. Best Pract. Res. Clin. Gastroenterol. (2001) 15:487-495.
24. MERKI HS, WILDER-SMITH CH: Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterol. (1994) 106:60-64.
25. GOLDLUST B, HEPBURN B, HARDIMAN Y: Nighttime dosing of omeprazole immediate-release oral suspension rapidly decreases nocturnal gastric acidity. Am. J. Gastroenterol. (2004) 99:S39 (Abstr. 116).
26. CASTELL D, GOLDLUST B, MORELLI G, MAJOR J, GAUTILLE T, HEPBURN B: Omeprazole immediate-release oral suspension is more effective than pantoprazole delayed-release tablets in reducing nighttime gastric acidity in GERD patients, Aliment Pharmacol. Ther. (2005) 21(12):1467-1474.
27. TAP PHARMACEUTICALS INC: Prevacid® IV prescribing information. TAP Pharmaceuticals, Inc., Lake Forest (IL), USA (2004).
28. WYETH PHARMACEUTICALS: Protonix® IV prescribing information. Wyeth Pharmaceuticals, Philadelphia (PA), USA (2004).
29. ASTRAZENECA: Nexium® IV prescribing information. AstraZeneca, Wilmington (DE), USA (2005).
30. LASKY MR, METZLER MH, PHILLIPS JO: A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J. Trauma (1998) 44(3):527-533.
31. SRINIVASAN R, TUTUIAN R, SCHOENFELD P et al.: Profile of GERD in the adult population of a north east urban community. J. Clin. Gastroenterol. (2004) 38:651-657.
32. FARUP C, KLEINMAN L, SLOAN S et al.: The impact of nocturnal symptoms associated with gastroesophageal reflux disease in health-related quality of life. Arch. Intern. Med. (2001) 161:45-52.
33. DEVAULT KR, CASTELL DO: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. (2005) 100:190-200.
34. O'CONNER JB, PROVENZALE D, BRAZER S: Economic considerations in the treatment of gastroesophageal reflux disease: a review. Am. J. Gastroenterol. (2000) 95:3356-3364.
35. TUTUIAN R, CASTELL D: Nocturnal acid breakthrough - approach to management. Medscape Gen. Med. (2004) 6(4): Posted 26 October 2004.
36. HAMMER J, SCHIMDT K: Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol. Ther. (2004) 19:1105-1110.
37. MARRONE GC, SILEN W: Pathogenesis, diagnosis and treatment of acute gastric mucosal lesions. Clin. Gastroenterol. (1984) 13(2):635-651.
38. ZINNER MJ, RYPINS EB, MARTIN LF et al.: Misoprostil versus antacid titration for preventing stress ulcers in postoperative ICU patients. Ann. Surg. (1989) 210:590-595.